Today: 19 July 2026
Sandisk stock price: SNDK holds near $627 with U.S. markets shut, eyes turn to Nvidia
16 February 2026
2 mins read

Sandisk stock price: SNDK holds near $627 with U.S. markets shut, eyes turn to Nvidia

New York, February 16, 2026, 10:05 EST — Market closed.

  • Sandisk finished Friday at $626.56, slipping 0.6% after a session marked by sharp swings.
  • Presidents Day keeps U.S. markets closed; trading starts up again Tuesday, with new U.S. data expected later in the week.
  • Nvidia’s results on Feb. 25 are shaping up as a crucial read on AI demand for chip and storage stocks.

Sandisk Corporation ended Friday at $626.56, slipping 0.6%, after moving from $586.37 to $661.50 through the session. After hours, shares picked up 0.6%, reaching $630.02.

With U.S. stock markets shut for Presidents Day on Monday, Sandisk holders are stuck with Friday’s closing price and just a handful of macro events on the calendar until trading picks up again Tuesday.

The pause is significant. Sandisk’s turned into a heavily trafficked AI storage bet, and its shares have proven quick to gap on even minor tweaks in risk appetite.

It’s still all about late January. Shares of Sandisk soared 14.7% on Jan. 30, driven by a new forecast for fiscal Q3 revenue between $4.4 billion and $4.8 billion and adjusted earnings of $12 to $14 a share. The sharp move also followed news that Sandisk will keep its flash-chip supply agreement with Japan’s Kioxia running through 2034. Morgan Stanley analysts don’t see the performance fading as long as AI demand stays this strong. Over at Morningstar, analysts pointed to supply bottlenecks that might not ease until at least 2028. The AI boost hasn’t been limited to Sandisk—Western Digital, Seagate and Micron are riding the same wave.

Sandisk reported on Jan. 29 that revenue for its fiscal second quarter climbed to $3.03 billion, with adjusted earnings landing at $6.20 a share. The company also stuck with its third-quarter outlook—the same targets that sparked January’s rally. CEO David Goeckeler emphasized stricter supply controls, describing Sandisk’s “structural reset to align supply with attractive, sustained demand” as a move to back “disciplined growth.” Sandisk

Friday drove the point home—volatility hasn’t let up on this stock, and it’s clear that a lot of the incremental buyers are just riding the cycle, not buying into the business itself.

The calendar could be the next catalyst. U.S. retail sales land Tuesday, followed by industrial production and the Fed’s minutes Wednesday, then GDP hits on Friday—data points that often jolt Treasury yields and ripple through higher-multiple tech stocks.

Investors have their eyes on Feb. 25, when Nvidia is set to hold a conference call at 2 p.m. PT (5 p.m. ET) to go over its fourth-quarter and full-year numbers—a key update for traders watching AI infrastructure budgets and their ripple effects on memory and storage.

Still, risks linger. Memory runs in cycles—if NAND shortages clear up quicker than the market’s betting, or if there’s a pause in cloud and AI capex, that would put new pressure on pricing and margins, especially now with expectations riding high.

Markets reopen Tuesday. Traders are eyeing Sandisk to see if it holds onto the low-$600s after last week’s volatility. Looking ahead, Feb. 25 is circled—Nvidia reports and analysts get their questions in.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Stock Fair Value and Performance in Focus
    July 19, 2026, 3:59 PM EDT. Neurocrine Biosciences (NBIX) is viewed as near fairly valued, with shares trading at a P/E ratio of 25.7x versus a fair value estimate of 26.0x. The stock has increased 73.4% over five years and posted a 29.4% gain in the past year, though this trails some competitors. Valuation signals are mixed, with about half indicating the stock could be expensive. Investors are assessing the resilience of cash flows from current therapies alongside operational risks. Growth prospects are supported by a broad pipeline, including late-stage assets and early commercial progress, yet policy changes and concentration risks are present. The overall assessment shows a valuation that reflects tempered expectations for Neurocrine's earnings potential and profitability.
Dauch (DCH) stock rises in early trade as board changes and exec share award hit filings
Previous Story

Dauch (DCH) stock rises in early trade as board changes and exec share award hit filings

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Next Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Go toTop